Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

5:00 PM ET Form 4
Insider Selling Donnelley Financial Solutions, Inc. DFIN

Donnelley Financial Solutions President - Key Accounts Eric J. Johnson Sells $1.02M of Stock

Eric J. Johnson, President - Key Accounts, sold 15,204 shares of Donnelley Financial Solutions, Inc. at $66.89 a share, worth $1.02M in total on Nov 6, 2026. Shares held after the trade: 101,610 (-13.0%).

Value
$1.02M
Shares
15,204
Price
$66.89
Role
President - Key Accounts
Holding change
-13.0%
Trade date
Nov 6, 2026
5:00 PM ET 8-K
Financial Results Dolphin Entertainment, Inc. DLPN

Dolphin Entertainment Financial Results

Dolphin Entertainment reported record quarterly revenue of $16.0 million for Q3 2026, an 8.3% year-over-year increase. The company achieved profitability with net income of $0.2 million and a 42.9% increase in Adjusted EBITDA to $1.6 million, driven by organic growth and improved operating leverage.

Term
Q3 2026

“Dolphin had an outstanding third quarter. Revenue for the quarter grew 8.3% year-over-year to $16.0 million, the highest quarterly revenue in Dolphin’s history, even including Q1 2024 when we reported $3.4 million from Blue Angels.”

Bill O’Dowd, CEO of Dolphin

“We reported net income of $0.2 million, compared to a net loss of $0.4 million a year ago, and adjusted EBITDA increased 42.9% to $1.6 million versus $1.1 million a year ago.”

Bill O’Dowd, CEO of Dolphin
5:00 PM ET Form 4
Insider Selling BeOne Medicines Ltd. ONC

BeOne Medicines Principal Accounting Officer Titus B. Ball Sells $632K of Stock

Titus B. Ball, Principal Accounting Officer, sold 1,559 shares of BeOne Medicines Ltd. at $405.55 to $406.34 a share (average $405.57) in 2 transactions, worth $632K in total on Nov 6, 2026. Shares held after the trade: 0 (-100.0%).

Value
$632K
Shares
1,559
Average price
$405.57
Role
Principal Accounting Officer
Holding change
-100.0%
Trade date
Nov 6, 2026
4:59 PM ET 10-Q
Financial Results Goldman Sachs Private Middle Market Credit II LLC

Goldman Sachs Private Middle Market Credit II Q3 2026 Results: Net Income $2.65M, Down 83.7% YoY

For the nine months ended September 30, 2026, Goldman Sachs Private Middle Market Credit II LLC reported total investment income of $113.26 million and net investment income of $70.61 million. The company experienced significant net unrealized depreciation of $55.19 million across its investment portfolio, contributing to a net asset value per unit of $65.20 compared to $68.62 at the end of 2025.

Key figure
Net income $2.65M · -83.7% YoY
4:59 PM ET 10-Q
Financial Results U.S. GoldMining Inc. USGO

U.S. GoldMining Q3 2026 Results: Net Loss of $8.19M, Loss Widens

U.S. GoldMining Inc. reported a significant increase in net loss to $14.3 million for the nine months ended September 30, 2026, compared to $5.0 million in the prior year, primarily driven by a surge in exploration expenses at the Whistler Project. The company remains in the exploration stage with no revenue, relying on equity financing including At-The-Market and registered direct offerings to fund its operations.

Key figure
Net loss $8.19M
4:59 PM ET 8-K
Loan & Debt AB Private Lending Fund

AB Private Lending Fund Debt Financing Update with The Bank of Nova Scotia

AB Private Lending Fund entered into a second amendment to its senior secured credit agreement with The Bank of Nova Scotia. The amendment extends the revolver availability period to November 6, 2030, and the final maturity date to November 6, 2031, while also resetting the minimum shareholders' equity test.

Counterparty
The Bank of Nova Scotia
Term
through Nov 2031
4:59 PM ET 10-Q
Financial Results Netlist Inc NLST ▶ Call

Netlist Q3 2026 Results: Turns Profitable, Net Income $85.4M

Netlist reported a significant increase in net sales to $105.1 million for the third quarter of 2026, driven by a $44.9 million license fee and strong product sales. The company achieved a net income of $85.4 million for the quarter, aided by a $44.0 million income tax benefit and a substantial increase in deferred revenue.

Key figure
Net income $85.4M
4:58 PM ET 10-Q
Financial Results Resideo Technologies, Inc. REZI ▶ Call

Resideo Technologies Q3 2026 Results: Net Income $22M, Down 85.9% YoY

Resideo Technologies reported a net income of $22 million for the third quarter of 2026, a significant decrease from $156 million in the prior year period. The company completed the ADI Spin-Off during the period, resulting in a substantial reduction in total assets from $8.4 billion to $4.1 billion and a shift to a retained deficit of $1.4 billion.

Key figure
Net income $22M · -85.9% YoY
4:58 PM ET 10-Q
Financial Results Veradermics, Inc MANE

Veradermics Q3 2026 Results: Net Loss of $21M, Loss Widens

Veradermics, Inc. is a clinical-stage biopharmaceutical company focused on developing VDPHL01 for pattern hair loss. As of November 5, 2026, the company had 42,195,472 shares of common stock outstanding and continues to incur substantial losses with no products yet approved for commercial sale.

Key figure
Net loss $21M
4:57 PM ET Form 4
Insider Buying TXO Partners, L.P. TXO

TXO Partners Director Bob R. Simpson Buys $3.08M of Stock

Bob R. Simpson, Director, bought 232,839 shares of TXO Partners, L.P. at $12.97 to $13.49 a share (average $13.22) in 3 transactions, worth $3.08M in total between Nov 6, 2026 and Nov 10, 2026. Shares held after the trade: 9,732,839 (+0.9%).

Value
$3.08M
Shares
232,839
Average price
$13.22
Role
Director
Holding change
+0.9%
Trade date
Nov 6, 2026 to Nov 10, 2026
4:56 PM ET 10-Q
Financial Results Apollo Origination II (UL) Capital Trust

Apollo Origination II Q3 2026 Results: Net Income $14.7M, Up 12.8% YoY

Apollo Origination II (UL) Capital Trust reported total investment income of $44.87 million for the nine months ended September 30, 2026, compared to $34.44 million in the prior year period. Net asset value per share decreased slightly to $25.39 from $25.55 at year-end 2025, primarily driven by net change in unrealized losses on investments.

Key figure
Net income $14.7M · +12.8% YoY
4:56 PM ET 10-Q
Financial Results Gevo, Inc. GEVO ▶ Call

Gevo Q3 2026 Results: Turns Profitable, Net Income $22.7M

Gevo, Inc. reported a significant net loss of $172.5 million for the nine months ended September 30, 2026, primarily driven by a $135.8 million impairment of long-lived assets and a $40.3 million allowance for credit losses. Despite these charges, total revenues grew to $172.4 million compared to $115.2 million in the prior year period, and the company generated positive cash flow from operations of $12.0 million.

Key figure
Net income $22.7M
4:56 PM ET 8-K
Loan & Debt AB Private Credit Investors Corp

AB Private Credit Investors Debt Financing Update with The Bank of Nova Scotia

AB Private Credit Investors Corp entered into a third amendment to its senior secured credit agreement with The Bank of Nova Scotia. The amendment extends the facility's maturity date from November 6, 2026, to November 8, 2027, and resets the minimum shareholders' equity compliance test.

Counterparty
The Bank of Nova Scotia
Term
through Nov 2027
4:56 PM ET 8-K
Investor Presentation Acrivon Therapeutics, Inc. ACRV

Acrivon Therapeutics Investor Presentation

Acrivon Therapeutics hosted a corporate R&D event and webcast featuring Key Opinion Leaders to introduce its new immunology and inflammation (I&I) programs, ACR-525 and a PKCθ inhibitor. The company filed a formal investor presentation deck detailing the preclinical programs and development plans for Eosinophilic esophagitis (EoE) identified via its AP3 platform.

4:55 PM ET 8-K
Capital Raise Hecla Mining Co HL

Hecla Mining Capital Raise

Hecla Mining Company entered into an Equity Distribution Agreement to establish an at-the-market (ATM) offering program for up to 50 million shares of common stock. Additionally, the company announced the redemption of all outstanding Series B Cumulative Convertible Preferred Stock for approximately $7.64 million and reported that Russell D. Lawlar has been re-appointed as Principal Accounting Officer following the departure of Stuart Absolom.

4:55 PM ET 10-Q
Financial Results Apollo Origination II (Levered) Capital Trust

Apollo Origination II Q3 2026 Results: Net Income $21.3M, Up 13.4% YoY

For the nine months ended September 30, 2026, Apollo Origination II (Levered) Capital Trust reported total investment income of $101.9 million and net investment income of $51.3 million. Total net assets grew to $835.9 million, driven by $105 million in net proceeds from common share issuances, despite a net change in unrealized losses of $12.4 million during the period.

Key figure
Net income $21.3M · +13.4% YoY
4:55 PM ET 8-K
M&A Deal Bunker Hill Mining Corp. BHLL

Bunker Hill Silver M&A Deal with Silver47 Exploration Corp.

Bunker Hill Silver Corp. completed its acquisition of Silver47 Exploration Corp. via a court-approved plan of arrangement, making Silver47 a wholly owned subsidiary. Silver47 shareholders received 0.1724 Bunker Hill shares for each Silver47 share held, creating a combined U.S. silver and critical minerals producer with a pro forma market capitalization of approximately $158 million.

Counterparty
Silver47 Exploration Corp.

“This merger represents a transformational and timely opportunity to create a leading American mining company focused on strengthening the US domestic metal supply chains at a time of intensifying global competition. I congratulate all our shareholders and the wider stakeholder community for supporting this important step forward for the Combined Company, and its potential to contribute to the revitalization of the US Mining Industry.”

Richard Williams, Executive Chairman of Bunker Hill

“Bunker Hill and Silver47 shareholders now own a compelling silver and critical mineral story in the United States: a producing mine in the Silver Valley and a pipeline of high-grade projects at Red Mountain, Hughes and Mogollon. With silver on the U.S. critical minerals list and strong support for domestic mining, we have the assets, the team and the timing to build a leading American silver producer. Thank you to all our shareholders. We are excited to get to work.”

Galen McNamara, President and Chief Investment Officer of Bunker Hill
4:54 PM ET 8-K
Dividend Orchid Island Capital, Inc. ORC

Orchid Island Capital Dividend

Orchid Island Capital declared a monthly cash dividend of $0.10 per share for November 2026, payable on December 31, 2026. The company also provided an operational update estimating its book value per share at $6.52 to $6.54 as of November 6, 2026, representing an 8-9% increase from September 30.

Term
month of November 2026
4:53 PM ET 10-Q
Financial Results T Series BDC LLC

T Series BDC Q3 2026 Results: Net Income $9.25M, Down 59.7% YoY

T Series BDC LLC's Form 10-Q for the period ended September 30, 2026, details its financial performance and investment activity as a business development company. The filing highlights net investment income, changes in net assets from operations, and the current fair value of its private debt and equity portfolio.

Key figure
Net income $9.25M · -59.7% YoY
4:52 PM ET 10-Q
Financial Results Petmed Express Inc PETS

Petmed Express Q2 2026 Results: Net Loss of $6.43M, Loss Narrows

PetMed Express reported a significant decline in net sales of 19.6% for the six months ended September 30, 2026, resulting in a net loss of $12.6 million. Management identified substantial doubt about the company's ability to continue as a going concern due to declining cash balances and ongoing operating losses, though they believe strategic cost reductions and marketing optimizations will alleviate these concerns.

Key figure
Net loss $6.43M
4:52 PM ET Form 4
Insider Selling Edwards Lifesciences Corp EW

Edwards Lifesciences Cvp, Tavr Daniel J. Lippis Sells $64.5K of Stock

Daniel J. Lippis, Cvp, Tavr, sold 619 shares of Edwards Lifesciences Corp at $104.25 a share, worth $64.5K in total on Nov 10, 2026. Shares held after the trade: 40,034 (-1.5%).

Value
$64.5K
Shares
619
Price
$104.25
Role
Cvp, Tavr
Holding change
-1.5%
Trade date
Nov 10, 2026
4:51 PM ET 8-K
Financial Results Gossamer Bio, Inc. GOSS

Gossamer Bio Financial Results

Gossamer Bio reported Q3 2026 financial results, highlighting the submission of its first New Drug Application (NDA) to the FDA for seralutinib in PAH. The company also noted a structured private placement that provided $25 million upfront and could unlock an additional $125 million upon FDA acceptance of the NDA. Additionally, the company completed a 1-for-80 reverse stock split in September 2026 to regain Nasdaq compliance.

Term
Q3 2026

“Submitting our first NDA marks an important milestone for Gossamer in our continued efforts to bring seralutinib to patients living with PAH. Furthermore, FDA acceptance of the application in 2026 would, subject to other customary closing conditions, unlock up to approximately $125 million in additional committed capital to support our priorities, including preparations for a potential launch. We remain focused on supporting the FDA’s review and preparing for a potential commercial launch of seralutinib in 2027.”

Faheem Hasnain, Chairman, Co-Founder and Chief Executive Officer
4:51 PM ET Form 4
Insider Selling Circle Internet Group, Inc. CRCL

Circle Internet Group Chief Product & Tech. Officer Nikhil Chandhok Sells $1.76M of Stock

Nikhil Chandhok, Chief Product & Tech. Officer, sold 26,668 shares of Circle Internet Group, Inc. at $66.09 a share, worth $1.76M in total on Nov 9, 2026. Shares held after the trade: 708,181 (-3.6%).

Value
$1.76M
Shares
26,668
Price
$66.09
Role
Chief Product & Tech. Officer
Holding change
-3.6%
Trade date
Nov 9, 2026
4:51 PM ET 10-Q
Financial Results Abvc Biopharma, Inc. ABVC

Abvc Biopharma Q3 2026 Results: Turns Profitable, Net Income $1.15M

ABVC BioPharma reported accrued research and development expenses of $1,741,083 as of September 30, 2026, primarily for manufacturing and process development. The company noted potential increases in future accruals due to the planned resumption of ophthalmology and CNS clinical trials.

Key figure
Net income $1.15M
4:51 PM ET 8-K
Nasdaq/NYSE Compliance Notice Rent the Runway, Inc. RENT

Rent the Runway Nasdaq/NYSE Compliance Notice

Rent the Runway received a deficiency notice from Nasdaq on November 4, 2026, because its market value of publicly held shares (MVPHS) fell below the $15 million minimum requirement for 39 consecutive business days. The company has 180 calendar days, until May 3, 2027, to regain compliance by maintaining a MVPHS of at least $15 million for ten consecutive business days. The company is evaluating options to resolve the deficiency, including a potential transfer to The Nasdaq Capital Market.

Counterparty
Nasdaq
Term
180 days
4:49 PM ET 10-Q
Financial Results Gossamer Bio, Inc. GOSS

Gossamer Bio Q3 2026 Results: Net Loss of $48.1M, Loss Narrows

Gossamer Bio reported total revenue of $64.6 million for the nine months ended September 30, 2026, compared to $34.7 million in the prior year, primarily driven by collaboration contracts. Despite the revenue growth, the company recorded a net loss of $77.8 million for the period, impacted by significant non-cash items including a $54.9 million remeasurement of warrant liability and a $43.8 million gain on debt extinguishment.

Key figure
Net loss $48.1M
4:48 PM ET 10-Q
Financial Results Autolus Therapeutics plc AUTL

Autolus Therapeutics Q3 2026 Results: Net Loss of $55.1M, Loss Narrows

Autolus Therapeutics plc, a foreign private issuer voluntarily filing a Form 10-Q, reported 266,340,330 ordinary shares outstanding as of November 9, 2026. The filing highlights the commercialization of AUCATZYL for adult r/r B-ALL and notes a restructuring and workforce reduction plan initiated in April 2026.

Key figure
Net loss $55.1M
4:48 PM ET 10-Q
Financial Results Metropolitan Life Insurance Co

Metropolitan Life Insurance Q3 2026 Results: Net Income $1.5B, Up 190.1% YoY

Metropolitan Life Insurance Company reported total assets of $375.9 billion as of September 30, 2026, a decrease from $383.5 billion at year-end 2025. Stockholder's equity declined to $12.4 billion, primarily driven by an increase in accumulated other comprehensive loss, while the company continues to operate as a wholly-owned subsidiary of MetLife, Inc. under a reduced disclosure format.

Key figure
Net income $1.5B · +190.1% YoY
4:47 PM ET 10-Q
Financial Results Hyliion Holdings Corp. HYLN

Hyliion Holdings Q3 2026 Results: Net Loss of $11.1M, Loss Narrows

Hyliion Holdings Corp. reported a net loss of $11.1 million for the third quarter of 2026, an improvement from the $13.3 million loss in the prior year period. Total revenues grew significantly to $7.5 million, primarily driven by research and development services, while the company continues to transition its focus toward the KARNO Power Module technology.

Key figure
Net loss $11.1M
4:47 PM ET Form 4
Insider Selling Seacoast Banking Corp of Florida SBCF

Seacoast Banking Corp of Florida Insider Dennis S. Hudson III Sells $34.3K of Stock

Dennis S. Hudson III sold 1,000 shares of Seacoast Banking Corp of Florida at $34.31 a share, worth $34.3K in total on Nov 9, 2026. Shares held after the trade: 8,356 (-10.7%).

Value
$34.3K
Shares
1,000
Price
$34.31
Holding change
-10.7%
Trade date
Nov 9, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.